Rizatriptan
Medication Facts
- Performance enhancing
- No
- Total hours to clear
- Not recorded
- Frequently used
- N/A
- ESC ID
- RIZATR-0796
- Trade names
- Maxalt
- Drug type
- 5-HT1 receptor agonist
- Plasma half-life · hours
- Not Published
- Equine dosing
- Consult Veterinarian
- Cmax · peak plasma concentration
- Not Published
- Tmax · time to peak plasma concentration
- Not Published
- ESC concentration guidance
- May not exceed 6% efficacy in plasma
- Primary withdrawal · hours
- 24
- Washout withdrawal · hours
- 0
- ESC control type
- C1 - Strictly Controlled - Restricted - Performance
- Medication report required
- MED REPORT REQUIRED
Uses & side effects
Product-specific side effects await source review.
Drug interactions
MAOIs (Monoamine Oxidase Inhibitors): Combining 5-HT1 agonists with MAOIs (e.g., phenelzine, linezolid, methylene blue) is contraindicated due to a high risk of serotonin syndrome. A 14-day washout period is typically recommended.Ergot Derivatives: Medications such as ergotamine, dihydroergotamine, or methysergide should not be used within 24 hours of a 5-HT1 agonist, as they can cause additive vasoconstriction.Serotonergic Antidepressants (SSRIs/SNRIs): Combining triptans with Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) may increase serotonin levels, creating a risk for serotonin toxicity, though some literature suggests the risk is low.Other Triptans: consult a licensed veterinarian to discuss treatment options before combining with with other 5-HT1 agonists.Other Agents: Caution should be used with antidepressants, including tricyclics and MAOIs, as well as substances like 5-HTP.Potential Adverse EffectsSerotonin Syndrome: Symptoms include agitation, confusion, tremor, tachycardia, and diarrhea.Cardiovascular Events: Vasospastic reactions such as coronary artery vasospasm or peripheral vascular ischemia may occur